Why some ovarian cancers resist platinum chemotherapy: changes in tumor metabolism
Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer
['FUNDING_OTHER'] · JESSE BROWN VA MEDICAL CENTER · NIH-11212826
This project looks at how ovarian tumors change their metabolism when they stop responding to platinum chemotherapy and seeks new targets and markers to help women with recurrent high-grade serous ovarian cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JESSE BROWN VA MEDICAL CENTER (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11212826 on ClinicalTrials.gov |
What this research studies
Researchers will combine three coordinated projects to study how high-grade serous ovarian tumors reprogram their metabolism as they become resistant to platinum drugs. They will analyze tumor samples and laboratory models to find metabolic pathways and biomarkers linked to resistance. The team aims to identify molecules that could be targeted with new therapies or used as tests to predict or monitor resistance. Findings will guide development of treatments designed specifically for platinum-resistant tumors.
Who could benefit from this research
Good fit: Ideal candidates would be women with high-grade serous ovarian carcinoma, particularly those with recurrent disease or documented platinum resistance.
Not a fit: People without ovarian cancer or those whose tumors remain platinum-sensitive are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to new tests and treatment strategies that specifically target metabolic changes in platinum-resistant ovarian cancer, potentially improving outcomes for affected patients.
How similar studies have performed: Laboratory and animal studies have shown metabolic changes can drive chemotherapy resistance and that targeting metabolism can work in preclinical models, but few metabolic-targeting approaches have yet proven effective in patients.
Where this research is happening
CHICAGO, UNITED STATES
- JESSE BROWN VA MEDICAL CENTER — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MATEI, DANIELA E — JESSE BROWN VA MEDICAL CENTER
- Study coordinator: MATEI, DANIELA E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer Cell, Cancer Patient, Cancers